Our official English website, www.x-mol.net, welcomes your
feedback! (Note: you will need to create a separate account there.)
Genome-wide CRISPR screen identifies MAD2L1BP and ANAPC15 as targets for brentuximab vedotin sensitivity in CD30+ peripheral T-cell lymphoma
Leukemia ( IF 12.8 ) Pub Date : 2024-10-21 , DOI: 10.1038/s41375-024-02441-1 Keito Suto, Norio Takei, Keito Yokoyama, Masahiro Chiba, Takashi Ishio, Michiyuki Maeda, Hideki Goto, Tomoyuki Endo, Takanori Teshima, Yibin Yang, Masao Nakagawa
中文翻译：
全基因组 CRISPR 筛选将 MAD2L1BP 和 ANAPC15 确定为 CD30+ 外周 T 细胞淋巴瘤中 brentuximab vedotin 敏感性的靶标
Leukemia ( IF 12.8 ) Pub Date : 2024-10-21 , DOI: 10.1038/s41375-024-02441-1 Keito Suto, Norio Takei, Keito Yokoyama, Masahiro Chiba, Takashi Ishio, Michiyuki Maeda, Hideki Goto, Tomoyuki Endo, Takanori Teshima, Yibin Yang, Masao Nakagawa
|
中文翻译：
全基因组 CRISPR 筛选将 MAD2L1BP 和 ANAPC15 确定为 CD30+ 外周 T 细胞淋巴瘤中 brentuximab vedotin 敏感性的靶标
京公网安备 11010802027423号